



Dra María Vila Dra Marta Londoño Parra

Servicio de Anestesia Reanimación y Tratamiento del Dolor Consorcio Hospital General Universitario de Valencia

- · Tipos de complicaciones:
  - Propias del paciente y de la comorbilidad asociada.
  - Propias de la técnica anestésica.
  - Propias de la cirugía.

# Complicaciones Propias del Paciente y sus comorbilidades

### Complicaciones propias del paciente y sus comorbilidades

- Enfermedad cardiovascular
- Enfermedades respiratorias
- Obesidad
- Diabetes
- Artritis reumatoidea y otras enfermedades reumatológicas



### Complicaciones propias del paciente y sus comorbilidades

Valoración preanestésica

Beta-Bloqueantes


Estatinas

Monitorización intraoperatoria

### Complicaciones propias del paciente y sus comorbilidades

Recommendations	Class <sup>b</sup>	Level
β-Blockers are recommended in patients who have known IHD or myocardial ischaemia according to pre-operative stress testing <sup>a</sup>	1	В
β-Blockers are recommended in patients scheduled for high-risk surgery <sup>a</sup>	1	В
Continuation of β-blockers is recommended in patients previously treated with β-blockers because of IHD, arrhythmias, or hypertension		С
β-Blockers should be considered for patients scheduled for intermediate-risk surgery <sup>a</sup>	lla	В
Continuation in patients previously treated with β-blockers because of chronic heart failure with systolic dysfunction should be considered	lla	С
β-Blockers may be considered in patients scheduled for low-risk surgery with risk factor(s)	llb	В
Perioperative high-dose β-blockers without titration are not recommended	Ш	Α
β-Blockers are not recommended in patients scheduled for low-risk surgery without risk factors	Ш	В
Treatment should be initiated optimally between 30 days refore surgery. Target: heart rate 60–70 beats/min, systoli >100 mmHg. Class of recommendation. Level of evidence.		

Recommendations	Class <sup>a</sup>	Levelb
It is recommended that statins be started in high-risk surgery patients, optimally between 30 days and at least 1 week before surgery	I	В
It is recommended that statins be continued perioperatively	I	С



### Complicaciones propias del paciente y sus comorbilidades

- Enfermedad cardiovascular
- Enfermedades respiratorias
- Obesidad
- Diabetes
- Artritis reumatoidea y otras enfermedades reumatológicas



### Complicaciones propias del paciente y sus comorbilidades

- Infecciones respiratorias agudas
- EPOC
- Asma
- Apnea obstructiva del sueño



### Complicaciones propias del paciente y sus comorbilidades

- Enfermedad cardiovascular
- Enfermedades respiratorias
- Obesidad
- Diabetes
- Artritis reumatoidea y otras enfermedades reumatológicas

### Complicaciones propias del paciente y sus comorbilidades

Am Acad Orthop Surg, voi 14, No /, July 2006, 425-432.

2006 the American Academy of Orthopaedic Surgeons

#### Obesidad

Perioperative Management of the Obese Orthopaedic Patient

Daniel Guss, MD and Timothy Bhattacharyya, MD

- Posicionamiento
- Manejo de la vía aérea
- Dificultad en las técnicas de bloqueo regional



### Complicaciones propias del paciente y sus comorbilidades

	Table 47-3 Medical Consequences of Obesity			
YSTEM PATHOLOGY				
Respiratory	Obstructive sleep apnea, obesity-hypoventilation syndrome, asthma, pulmonary hypertension			
Cardiovascular	Dysrhythmias, atherosclerosis, cardiac failure, coronary artery disease, peripheral vascular disease, sudden cardiac death, systemic hypertension, thromboembolism, varicose veins			
Gastrointestinal	Colon cancer, gallbladder disease, gastroesophageal reflux disease, hernias, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis			
Endocrine/metabolic	Diabetes mellitus, dyslipidemia, hyperinsulinemia, hypothyroidism, insulin resistance, metabolic syndrome			
Genitourinary	End-stage renal disease, macrosomia, menorrhagia, preeclampsia and eclampsia, prostate cancer, urinary incontinence			
Neurologic	Carpal tunnel syndrome, pseudotumor cerebri, stroke			
Hematology	Hypercoagulability, polycythemia			
Musculoskeletal	Acanthosis nigricans, gout, osteoarthritis, rheumatoid arthritis			
Psychology/psychiatry	Depression, reduced self-esteem, social stigma			
1				

### Complicaciones propias del paciente y sus comorbilidades

- Enfermedad cardiovascular
- Enfermedades respiratorias
- Obesidad
- Diabetes
- Artritis reumatoidea y otras enfermedades reumatológicas



### Complicaciones propias del paciente y sus comorbilidades

- Diabetes Mellitus:
  - > riesgo de infecciones
  - > riesgo de infecciones de herida quirúrgica
  - > tiempo de cicatrización
  - > riesgo de IM perioperatorio y ACV



"Diabetes has increased dramatically over the past 10 years. That proves that diabetes is caused by global warming!"

### Complicaciones propias del paciente y sus comorbilidades

- Plan with the surgeon to schedule the surgery as the first case of the day to prevent prolonged fasting.
- As a general rule, oral hypoglycemic agents are held on the day of surgery to avoid reactive hypoglycemia. The exception is metformin, which should be held
  for at least 24 hours preoperatively to avoid the risk drug-induced lactic acidosis.
- Insulin should be continued through the evening before surgery, including the usual dose of insulin glargine (Lantus).
- Patients should be counseled to take a glucose tablet or clear juice if hypoglycemia occurs prior to arrival at the hospital, in order to prevent delay of the surgery.
- Schedule the patient to arrive without having ingested anything by mouth in early morning and check blood glucose, electrolytes, and ketones.
- Type 1 diabetics should be continued on basal insulin replacement even while nothing by mouth status to prevent ketoacidosis. Administer half the usual morning dose of intermediate- or long-acting insulin after arrival to the surgery center, but hold the usual dose of rapid- or short-acting insulin.
- Patients on insulin pumps may be managed by continuing the pump for short surgeries, or changing over to an intravenous insulin infusion for moderate or major surgeries.
- Use the patient's own sliding scale to administer a short-acting insulin subcutaneously to maintain the glucose between 100 and 200 mg/dL prior to the scheduled surgery.


### Complicaciones propias del paciente y sus comorbilidades

- Enfermedad cardiovascular
- Enfermedades respiratorias
- Obesidad
- Diabetes
- Artritis reumatoidea y otras enfermedades reumatológicas



### Complicaciones propias del paciente y sus comorbilidades

- Artritis reumatoidea
  - Deformidad articular
    - Técnicas locorregionales
    - Posición quirúrgica
  - Afectación sistémica



### Complicaciones propias del paciente y sus comorbilidades

#### Table 25-12 Extra-Articular Manifestations of Rheumatoid Arthritis

#### Skin

Raynaud phenomenon Digital necrosis

#### Eyes

Scleritis

Corneal ulceration

#### Lung

Pleural effusion

Pulmonary fibrosis

#### Heart

Pericarditis

Cardiac tamponade

Coronary arteritis

Aortic insufficiency

#### Kidney

Interstitial fibrosis

Glomerulonephritis

Amyloid deposition

#### Peripheral Nervous System

Compression syndromes

Mononeuritis

#### **Central Nervous System**

**Dural nodules** 

Necrotizing vasculitis


#### Liver

Hepatitis

#### Blood


Anemia

Leukopenia



SARTD-CHGUV Sesión de Formación Continuada Valencia 27 de Junio de 2010

٠



- Dificultad en el manejo de la vía aérea.
- Anquilosis columna cervical
- Inestabilidad cervical
- •Hipoplasia mandibular
- Desviación de la laringe

## complicaciones Propias de la tecnica anestésica

#### Complicaciones propias de la técnica anestésica

- Toxicidad por anestésicos locales
- Complicaciones infecciosas
- Complicaciones por bloqueos neuroaxiales
- Complicaciones por bloqueos periféricos



#### Complicaciones propias de la técnica anestésica

- Toxicidad por anestésicos locales
  - Tipo de fármaco
  - Dosis administrada
  - Factores anatómicos
  - Patología asociada



#### Complicaciones propias de la técnica anestésica

	Та	ble 21-9 Clinical Pro	file of Local A	nesthetics	M
LOCAL ANESTHETIC	CONCENTRATION (%)	ON CLINICAL USE	ONSET	DURATIO (hr)	NRECOMMENDED MAXIMUM SINGLE DOSE (mg)
AMIDES					
Bupivacaine	0.25	Infiltration	Fast	2–8	175/225 + epinephrine
Levobupivacaine	0.25-0.5	Peripheral nerve block	Slow	4–12	150
	0.5–0.75	Epidural anesthesia	Moderate	2–5	150
	0.03-0.25	Epidural analgesia	NA	NA	NA
	0.5–0.75	Spinal anesthesia	Fast	1–4	20

Lidocaine	0.5–1	Infiltration	Fast	1-4	300/500 + epinephrine
	0.25-0.5	IV regional anesthesia	Fast	0.5–1	300
1–1.5 1.5–2 1.5–5	1–1.5	Peripheral nerve block	Fast	1–3	300/500 + epinephrine
	1.5–2	Epidural anesthesia	Fast	1–2	300/500 + epinephrine
	1.5–5	Spinal anesthesia	Fast	0.5–1	100
	4	Topical	Fast	0.5–1	300
Mepivacaine 0.5–1	0.5–1	Infiltration	Fast	1–4	400/500 + epinephrine
	1–1.5	Peripheral nerve block	Fast	2-4	400/500 + epinephrine
	1.5–2	Epidural anesthesia	Fast	1–3	400/500 + epinephrine
	2–4	Spinal anesthesia	Fast	1–2	100

#### Complicaciones propias de la técnica anestésica

Ropivacaine	0.2-0.5	Infiltration	Fast	2–6	200	
	0.5–1	Peripheral nerve block	Slow	5–8	250	
	0.5–1	Epidural anesthesia	Moderate	2–6	200	
	0.05-0.2	Epidural analgesia	NA	NA	NA	

#### Complicaciones propias de la técnica anestésica

• Tipo de anestésico local

• Tipo de bloqueo

Table 21-8 Relative Potency for Systemic Central Nervous System Toxicity by Local Anesthetics and Ratio of Dosage Needed Cardiovascular System: Central Nervous System (CVS:CNS) Toxicity				
GENT	RELATIVE POTENCY FOR CNS TOXICITY	CVS:CNS		
Bupivacaine	4.0	2.0		
Levobupivacaine	2.9	2.0		
Chloroprocaine	0.3	3.7		
Etidocaine	2.0	4.4		
Lidocaine	1.0	7.1		
Mepivacaine	1.4	7.1		
Prilocaine	1.2	3.1		
Procaine	0.3	3.7		
Ropivacaine	2.9	2.0		
Tetracaine	2.0			

Data from Liu SS: Local Anesthetics and Analgesia, The Management of Pain. Edited by Ashburn MA, Rice LJ. New York, Churchill Livingstone, 1997, pp 141; and Groban L: Central nervous system and cardiac effects from long-acting amide local anesthetic toxicity in the intact animal model. Reg Anesth Pain Med 2003; 28: 3.

Table 21-6 Typical C <sub>max</sub> After Regional Anesthetics with Commonly Used Local Anesthetics					
LOCAL ANESTHETIC	TECHNIQUE	DOSE (mg)	Cmax (µg/mL)	T <sub>max</sub> (min)	TOXIC PLASMA CONCENTRATION (µg/mL)
Bupivacaine	Brachial plexus	150	1.0	20	3
	Celiac plexus	100	1.50	17	
	Epidural	150	1.26	20	
	Intercostal	140	0.90	30	
	Lumbar sympathetic	52.5	0.49	24	
	Sciatic femoral	400	1.89	15	
evobupivacaine Epidural	Epidural	75	0.36	50	4
8	Brachial plexus	250	1.2	55	
idocaine Brachial plexus	4 THE SECTION AND ADMINISTRATION OF THE SECTION OF	400	4.00	55 25 20	5
	Epidural	400	4.27	20	
	Intercostal	400	0.8	15	
Mepivacaine	Brachial plexus	500	3.68	24	5
	Epidural	500	4.95	16	
	Intercostal	500	8.06	9	
	Sciatic/femoral	500	3.59	31	
Ropivacaine	Brachial plexus	190	1.3	53	4
D00-40-00-000-00-00-00-00-00-00-00-00-00-	Epidural	150	1.07	40	
	Intercostal	140	1.10	21	

C<sub>max</sub>, peak plasma levels; T<sub>max</sub>, time until C<sub>max</sub>.

Data from Liu SS: Local anesthetics and analgesia, The Management of Pain. Edited by Ashburn MA, Rice LJ. New York, Churchill Livingstone, 1997, pp 141. Berrisford RG: Plasma concentrations of bupivacaine and its enantiomers during continuous extrapleural intercostal nerve block. Br J Anaesth 1993; 70: 201. Kopacz DJ: A comparison of epidural levobupivacaine 0.5% with or without epinephrine for lumbar spine surgery. Anesth Analg 2001; 93: 755. Crews JC: Levobupivacaine for axillary brachial plexus block: A pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. Anesth Analg 2002; 95: 219.

#### Complicaciones propias de la técnica anestésica

CLÍNICA

#### **NEUROLÓGICA**

**CARDIOVASCULAR** 

Dosis bajas: depresión SNC

**Leve:** Hipotensión, Bradicardia e Hipoxia



Dosis medias: Excitabilidad del SNC

Severa: Colapso cardiovascular, arritmias ventriculares.



Dosis altas: Convulsiones y coma

#### ASRA Practice Advisory on Local Anesthetic Systemic Toxicity

Joseph M. Neal, MD,\* Christopher M. Bernards, MD,\* John F. Butterworth, IV, MD,†
Guido Di Gregorio, MD,‡ Kenneth Drasner, MD,§ Michael R. Hejtmanek, MD,\* Michael F. Mulroy, MD,\*
Richard W. Rosenquist, MD,// and Guy L. Weinberg. MD;

\*\*The control of the control

#### TABLE 3. Recommendations for Diagnosing LAST

- Classic descriptions of LAST depict a progression of subjective symptoms of CNS excitement (agitation, auditory changes, metallic taste or abrupt onset of psychiatric symptoms), followed by seizures then CNS depression (drowsiness, coma, or respiratory arrest). Near the end of this continuum, initial signs of cardiac toxicity (hypertension, tachycardia, or ventricular arrhythmias) are supplanted by cardiac depression (bradycardia, conduction block, asystole, decreased contractility). However, there is substantial variation in this classic description, including:
  - Simultaneous presentation of CNS and cardiac toxicity
  - Cardiac toxicity without prodromal signs and symptoms of CNS toxicity
  - Thus, the practitioner must be vigilant for atypical or unexpected presentation of LAST (I; B).
- The timing of LAST presentation is variable. Immediate (<60 s) presentation suggests intravascular injection of local anesthetic with direct access to the brain, whereas presentation that is delayed 1–5 mins suggests intermittent intravascular injection, lower extremity injection, or delayed tissue absorption. Because LAST can present >15 mins after injection, patients that receive potentially toxic doses of local anesthetic should be closely monitored for at least 30 mins after injection (I; B).
- Case reports associate LAST with underlying cardiac, neurologic, pulmonary, renal, hepatic, or metabolic disease. Heightened vigilance may be warranted in these patients, particularly if they are at the extremes of age (IIa; B).
- The overall variability of LAST signs and symptoms, timing of onset, and association with various disease states suggests that practitioners should maintain a low threshold for considering the diagnosis of LAST in patients with atypical or unexpected presentation of CNS or cardiac signs and symptoms after receiving more than a minimal dose of local anesthetic (IIa; B).

#### SPECIAL ARTICLE


#### ASRA Practice Advisory on Local Anesthetic Systemic Toxicity

Joseph M. Neal, MD,\* Christopher M. Bernards, MD,\* John F. Butterworth, IV, MD,†
Guido Di Gregorio, MD,‡ Kenneth Drasner, MD,§ Michael R. Hejtmanek, MD,\* Michael F. Mulroy, MD,\*
Richard W. Rosenquist, MD,// and Guy L. Weinberg, MD+


ZA COMPA CONCENTION	TION (µg/mL)EFFECT
1–5	Analgesia
5–10	Lightheadedness Tinnitus Numbness of tongue
10–15	Seizures Unconsciousness
15–25	Coma Respiratory arrest
>25	Cardiovascular depression

#### Complicaciones propias de la técnica anestésica

 Tratamiento de la intoxicación








#### TABLE 4. Recommendations for Treatment of LAST

- If signs and symptoms of LAST occur, prompt and effective airway management is crucial to preventing hypoxia and acidosis, which are known to potentiate LAST (I; B).
- If seizures occur, they should be rapidly halted with benzodiazepines. If benzodiazepines are not readily available, small doses of propofol or thiopental are acceptable. Future data may support the early use of lipid emulsion for treating seizures (I; B).
- Although propofol can stop seizures, large doses further depress cardiac function; propofol should be avoided when there are signs of CV compromise (III; B). If seizures persist despite benzodiazepines, small doses of succinylcholine or similar neuromuscular blocker should be considered to minimize acidosis and hypoxemia (I; C).
- If cardiac arrest occurs, we recommend standard Advanced Cardiac Life Support with the following modifications:
  - If epinephrine is used, small initial doses (10–100 μg boluses in the adult) are preferred (IIa; C)
  - · Vasopressin is not recommended (III; B)
  - Avoid calcium channel blockers and β-adrenergic receptor blockers (III; C)
  - If ventricular arrhythmias develop, amiodarone is preferred (IIa; B); treatment with local anesthetics (lidocaine or procainamide) is not recommended (III; C)
- Lipid emulsion therapy (IIa; B):
  - Consider administering at the first signs of LAST, after airway management
  - o Dosing:
  - 1.5 mL/kg 20% lipid emulsion bolus
  - 0.25 mL/kg per minute of infusion, continued for at least 10 mins after circulatory stability is attained
  - If circulatory stability is not attained, consider rebolus and increasing infusion to 0.5 mL/kg per minute
  - Approximately 10 mL/kg lipid emulsion for 30 mins is recommended as the upper limit for initial dosing
- Propofol is not a substitute for lipid emulsion (III; C).
- Failure to respond to lipid emulsion and vasopressor therapy should prompt institution of cardiopulmonary bypass (CPB) (IIa; B). Because there can be considerable lag in beginning CPB, it is reasonable to notify the closest facility capable of providing

SARTD-CHGUV Sesion de Formación Continuada

The class of reValencia, 27d de Junio, de 2010, tervention are given in parenthesis (Table 1).





Intralipid 20% 1-2ml/Kg x 1 min

#### Identificacion pacientes alto riesgo TAL

Trastornos conducción cardiaca Cardiopatía isquémica Edades extremas de vida <4 />70



#### PREVENCION

Minimas dosis totales AL (Volumen X concentración).

Inyección Al. fraccionada 3-5 ml e intervalo de 1T circulación entre dosis(30-45seg).

Aspiraciones repetidas (falso - 2%).

Uso potenciales dosis tóxicas añadir A puede ser útil (controvertido).

Uso US reduce incidencia punción vascular/ no existe evidencia de disminuir intoxicación



#### TRATAMIENTO

- 1. Asegurar via aérea: evitar hipoxia y acidosis.
- 2.En caso convulsiones: BZA fármaco de elección, y dosis bajas de propofol o thiopental.
- 3.En caso parada cardiaca:
  - -Aplicar protocolos PCR + soporte vital avnazado.
  - -Si administración de A se recomiendan dosis algo menores 10-100µg iy.
  - -Evitar Ca-antagonistas/B-Bloqueantes.
  - -Si arritmias ventriculares amiodarona es fármaco de elección.
- 4. Terapia emulsión lipídica.
- -Dosis inicio: 1,5 ml/Kg 20% en bolus.
- -Dosis mantenimiento 0,25ml/Kg/min .Dosis máximas: 10ml/Kg/30 minutos.
- 5.En caso de fracaso de anteriores medidas se recomienda Derivación cardiopulmonar.

#### Complicaciones propias de la técnica anestésica

- Toxicidad por anestésicos locales
- Complicaciones infecciosas
- Complicaciones hemorrágicas
- Complicaciones por bloqueos neuroaxiales
- Complicaciones por bloqueos periféricos



#### Complicaciones propias de la técnica anestésica

British Journal of Anaesthesia 96 (3): 292-302 (2006) doi:10.1093/bja/ael006 Advance Access publication January 23, 2006 BJA

#### REVIEW ARTICLE

#### **Epidural abscesses**

S. Grewal<sup>1</sup>\*, G. Hocking<sup>1</sup> and J. A. W. Wildsmith<sup>2</sup>

- (i) <u>Compromised immunity</u>: diabetes mellitus, steroid or other immunosuppressive therapy, malignancy, pregnancy, HIV infection, alcoholism and cirrhosis. 108 135
- (ii) Disruption of the spinal column: degenerative disease and disruption by trauma, surgery or instrumentation, including discography, chemonucleosis and central neuraxial block, the latter also providing a direct portal for organisms. Even temporally distant blunt trauma is a risk factor.<sup>29</sup>
- (iii) Source of infection: respiratory, urinary and minor soft tissue infections may all act as primary sources of haematogenous spread; i.v. drug abusers are constantly at risk, as are patients with indwelling vascular catheters.



iflammation and infection complications of 2285 perineural catheters: a prospective study

M. Neuburger 1, J. Büttner 1, S. Blumenthal 2, J. Breitbarth 1 A. Borgeat 2

Department of Anesthesiology, Berufsgenossenschaftliche Unfallklinik Murnau, Germany and Department of Anesthesiology, Orthopedic University Hospital Balgrist, Zurich,

### Complicaciones propias de la técnica anestésica

- Toxicidad por anestésicos locales
- Complicaciones infecciosas
- Complicaciones hemorrágicas
- Complicaciones por bloqueos neuroaxiales
- Complicaciones por bloqueos periféricos




### Complicaciones propias de la técnica anestésica

ASRA PRACTICE ADVISORY

Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy

American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition)

- Complicaciones hemorrágicas
  - Localización del bloqueo
  - Medicación habitual



### Complicaciones propias de la técnica anestésica

- Toxicidad por anestésicos locales
- Complicaciones infecciosas
- Complicaciones por bloqueos neuroaxiales
- Complicaciones por bloqueos periféricos




Complicaciones propias de la técnica anestésica

- Bloqueos neuroaxiales:
  - Bloqueo simpático
  - Anestesia espinal total
  - Hematoma epidural
  - Síntomas neurológicos transitorios
  - Punción dural accidental y CPPD







### Complicaciones propias de la técnica anestésica

- Bloqueos neuroaxiales:
- Bloqueo simpático:
- Síntomas: Hipotensión y bradicardia.
- Tto: Fármacos vasomotores.





### Complicaciones propias de la técnica anestésica

- Bloqueos neuroaxiales:
- Anestesia espinal total
- Síntomas: Disnea o apnea, nauseas, hipotensión y/o bradicardia.
- Tto: Actuar rápido- Soporte ventilatorio y fármacos vasopresores

Dosis test y aspirar antes de colocar AL





### Complicaciones propias de la técnica anestésica

• Bloqueos neuroaxiales:

Descompresión en 6 a 8 h

- Hematoma epidural
- Síntomas: Dolor de espalda irradiado a piernas, debilidad motora y disfunción de esfínteres
- Manejo: TAC o RMN de urgencia y valoración por NUC





#### Table 2. Recommendations: Limiting, Diagnosing, and Treating Neuraxial Injury

#### Limiting injury

- Misidentification of vertebral level, unrecognized lateral needle placement or deviation, abnormal caudad termination of the spinal cord, or failure of the ligamentum flavum to fuse in the midline may contribute to direct needle injury to the spinal cord. Clinicians are advised to be aware of these anatomic conditions, particularly in patients with challenging surface anatomy. (Class I)
- Clinicians are advised to be aware of and to avoid conditions that have been linked to the formation of epidural hematoma or
  epidural abscess, as noted in previous ASRA Practice Advisories. Such conditions include concurrent or imminent
  anticoagulation, the use of multiple anticoagulants, improper aseptic technique, and needle placement during untreated active
  infection.<sup>1,3</sup> (Class I)
- Patients with known tumor in the epidural space should undergo neuraxial imaging studies to define the extent of tumor mass. If the tumor is close to the planned site of epidural solution injection, alternative methods of anesthesia or analgesia should be considered. (Class II)
- Surgical positioning and specific space-occupying extradural lesions (e.g., severe spinal stenosis, epidural lipomatosis, ligamentum flavum hypertrophy, or ependymoma) have been associated with temporary or permanent spinal cord injury in conjunction with neuraxial regional anesthetic techniques. These conditions are particularly relevant when they coexist with an epidural hematoma or abscess. Awareness of these conditions should prompt consideration of risk vs. benefit when contemplating neuraxial regional anesthetic techniques. (Class II)
- Initial dosing or redosing of subarachnoid local anesthetic in excess of the maximum recommended dose may increase the risk of spinal cord or spinal nerve root neurotoxicity and should be avoided. (Class I)
- Epidural anesthetic procedures using the thoracic approach are neither safer nor riskier than using the lumbar approach.
   (Class I)
- The use of local anesthetic and/or opioid during neuraxial block for chronic pain treatments in the ambulatory setting should be
  accompanied by the same close monitoring and ability to perform resuscitative maneuvers that are available to those patients
  receiving neuraxial local anesthetic and/or opioid in the operating room. (Class I)

#### Diagnosis and treatment

- Magnetic resonance imaging (MRI) is the diagnostic modality of choice for suspected neuraxial lesions. Computed tomography
  (CT) should be used for rapid diagnosis if MRI is not immediately unavailable, especially when neuraxial compression injury is suspected. (Class I)
- Diagnosis of a compressive lesion within or near the neuraxis demands immediate neurosurgical consultation for consideration of decompression. (Class I)

### Complicaciones propias de la técnica anestésica

- Bloqueos neuroaxiales:
- Síntomas neurológicos transitorios
- Punción dural accidental y cefalea postpuncion dural accidental





### Complicaciones propias de la técnica anestésica


- Toxicidad por anestésicos locales
- Complicaciones infecciosas
- Complicaciones por bloqueos neuroaxiales
- Complicaciones por bloqueos periféricos



### Complicaciones propias de la técnica anestésica

Neurological Complications After Regional Anesthesia: Contemporary Estimates of Risk

- Difusión espinal
- Lesiones neurológicas
- Otros: Paresia
   hemidiafragmática,
   neumotórax...



Marnie B. Welch, M.D.,\* Chad M. Brummett, M.D.,† Terrence D. Welch, M.D.,‡ Kevin K. Tremper, Ph.D., M.D.,§

Con Amy M. Shanks, M.S., Pankaj Guglani, M.D., George A. Mashour, M.D., Ph.D.#

### cirugía ortopédica y traumatológica

#### Table 3. Recommendations: Limiting, Diagnosing, and Treating Peripheral Nerve Injury

#### Limiting injury

- There are no animal or human data to support the superiority of one nerve localization technique—paresthesia, nerve stimulation, ultrasound—over another with regards to reducing the likelihood of nerve injury. (Class I)
- Animal data have linked high injection pressures to subsequent fascicular injury, but there are no human data that confirm or refute the effectiveness of injection pressure monitoring for limiting nerve injury. (Class II)
- There are no human data to support the superiority of one local anesthetic or additive over another with regards to reducing the likelihood of neurotoxicity. (Class I)
- Patients with diseased or previously injured nerves (e.g., diabetes mellitus, severe peripheral vascular disease, or chemotherapy)
  may theoretically be at increased risk for block-related nerve injury. Although isolated case reports have described new or
  progressive neurologic deficits after regional anesthetic techniques in patients with multiple sclerosis or previous exposure to
  chemotherapy, clinical experience can neither refute nor confirm these concerns. Based on limited animal data, consideration
  may be given to avoiding more potent local anesthetics, reducing local anesthetic dose and/or concentration, and avoiding or
  limiting vasoconstrictive additives in these patients. (Class II)
- If damage to protective tissue barriers such as the perineurium is suspected from an abnormally painful paresthesia or pain on injection of local anesthetic, further injection should be halted immediately, and the needle repositioned. (Class I) Consideration may be given to aborting the block procedure so as to avoid further deposition of local anesthetic and additive. (Class III)

#### Diagnosis and treatment

- Complete absence of nerve function beyond the duration of the anesthetic or the progression of neurologic deficit(s) should prompt urgent neurological or neurosurgical consultation and evaluation. (Class I)
- Incomplete lesions associated with moderate-to-severe neural deficit should prompt neurologic consultation and evaluation for consideration of electrophysiological studies and/or radiologic imaging. Consideration should be given to bilateral examination and early studies to establish baseline, pre-existing lesions, and prognosis. (Class I)
- Nerve lesions that fail to resolve 2 to 5 months after initial neurological evaluation should prompt consideration of neurosurgical consultation. (Class II)

# complicaciones Propias de la cirugía

### Complicaciones propias de la cirugía

- Dependientes de la posición
- Debidas al torniquete
- Sd cementación ósea
- Embolia grasa y gaseosa
- TVP y TEP



### Complicaciones propias de la cirugía Posición quirúrgica



Anesthesiology 2009; 111:490-7

Copyright © 2009, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

#### Perioperative Peripheral Nerve Injuries

A Retrospective Study of 380,680 Cases during a 10-year Period at a Single Institution

Marnie B. Welch, M.D.,\* Chad M. Brummett, M.D.,† Terrence D. Welch, M.D.,‡ Kevin K. Tremper, Ph.D., M.D.,§ Amy M. Shanks, M.S., Pankaj Guglani, M.D.,† George A. Mashour, M.D., Ph.D.#

### Complicaciones propias de la cirugía Torniquete de isquemia



### Complicaciones propias de la cirugía



### Torniquete de isquemia

Acidosis metabólica

FC
PaCO2
Potasio

Embolismo cerebral

### Complicaciones propias de la cirugía

Conjunto de síntomas que pueden incluír: Hipoxia, hipotensión, arritmias y/o incremento de la resistencia vascular pulmonar



SARTD-CHGUV Sesión de Formación Continuada Valencia 27 de Junio de 2010

British Journal of Anaesthesia 102 (1): 12-22 (2009) doi:10.1093/bja/aen328

### BJA

#### Bone cement implantation syndrome

A. J. Donaldson<sup>1</sup>, H. E. Thomson<sup>1</sup>, N. J. Harper<sup>2\*</sup> and N. W. Kenny<sup>3</sup>

Grado	Clínica
1	Hipoxia moderada (SatO2 mayor 94%) o Hipotensión (caída TAS mayor 20%)
2	Hipoxia severa (SatO2 menor 88%) o Hipotensión (caída TAS mayor 40%) o pérdida de la conciencia
3	Colapso cardiovascular que requiere RCP



### Complicaciones propias de la cirugía

#### Table 4 Significant risk factors for developing BCIS

Pre-existing disease

Pre-existing pulmonary hypertension

Significant cardiac disease

New York Heart Association class 3 or 4

Canadian Heart Association class 3 or 4

Surgical factors

Pathological fracture

Inter-trochanteric fracture

Long-stem arthroplasty



### Complicaciones propias de la cirugía

#### Table 53-4 Criteria for Diagnosis of Fat Embolus Syndromea

#### MAJOR

Axillary/subconjunctival petechiae Hypoxemia (Pao<sub>2</sub> <60 mm Hg; FIO<sub>2</sub> <0.4) Central nervous system depression (disproportionate to hypoxemia) Pulmonary edema

Embolia grasa

#### MINOR

Tachycardia (>110 beats/min)

Hyperthermia

Retinal fat emboli

Urinary fat globules

Decreased platelets/hematocrit (unexplained)

Increased erythrocyte sedimentation rate

Fat globules in sputum

<sup>a</sup>Diagnosis of fat embolus syndrome requires at least one sign from the major and four signs from the minor criteria categories. From Gurd AR: Fat embolism: An aid to diagnosis. J Bone Joint Surg Br 1970; 52: 732, with permission.

1

#### Complicaciones propias de la cirugía: TVP y TEP

Table 8—VTE Prevalence After Major Orthopedic Surgery (Section 3.0)\*

	DVT, %		PE, %	
Procedures	Total	Proximal	Total	Fatal
Hip arthroplasty	42-57	18-36	0.9-28	0.1-2.0
Knee arthroplasty	41-85	5-22	1.5-10	0.1-1.7
HFS	46-60	23-30	3-11	0.3 - 7.5

<sup>\*</sup>DVT rates are based on the use of mandatory venography in prospective clinical trials published between 1980 and 2002 in which patients received either no thromboprophylaxis or placebo. PE rates were derived from prospective studies that may have used thromboprophylaxis. From Geerts et al.<sup>1</sup>



#### Complicaciones propias de la cirugía: TVP y TEP

Table 5—Levels of Thromboembolism Risk and Recommended Thromboprophylaxis in Hospital Patients (Section 1.3)\*

Levels of Risk	Approximate DVT Risk Without Thromboprophylaxis, %†	Suggested Thromboprophylaxis Options‡
Low risk		25 25 25 V5525
Minor surgery in mobile patients	< 10	No specific thromboprophylaxis
Medical patients who are fully mobile		Early and "aggressive" ambulation
Moderate risk		
Most general, open gynecologic or urologic surgery patients	10-40	LMWH (at recommended doses), LDUH bid of tid, fondaparinux
Medical patients, bed rest or sick		
Moderate VTE risk plus high bleeding risk		Mechanical thromboprophylaxis§
High risk		
Hip or knee arthroplasty, HFS	40-80	LMWH (at recommended doses), fondaparinux,
Major trauma, SCI		oral vitamin K antagonist (INR 2-3)
High VTE risk plus high bleeding risk		Mechanical thromboprophylaxis§


<sup>\*</sup>The descriptive terms are purposely left undefined to allow individual clinician interpretation.


‡See relevant section in this chapter for specific recommendations.

Mechanical thromboprophylaxis includes IPC or VFP and/or GCS; consider switch to anticoagulant thromboprophylaxis when he decreases.




<sup>†</sup>Rates based on objective diagnostic screening for asymptomatic DVT in patients not receiving thromboprophylaxis.







SARTD-CHGUV Sesión de Formación Continuada Valencia 27 de Junio de 2010



### Gracias!!!